Sulzer Medica gets rights to bone tissue product
This article was originally published in Clinica
Swiss company Sulzer Medica is to strengthen its spinal portfolio through a marketing and distribution agreement with Tutogen Medical for its Tutoplast human bone tissue products for spinal applications. Sulzer will pay $3 million over two years for the rights to the products, which address the $1 billion spinal fusion market. The two companies will also collaborate on the development of a range of proprietary tissue products and implants.
You may also be interested in...
Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.
While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.
As a freshman member on the US House Energy and Commerce Committee, former St. Jude Medical exec Rep. Angie Craig can help shape future health care, cybersecurity bills.